Emma Aitken

Emma Aitken

Auto-generated profile, based on publicly available information

Emma Aitken

Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in The Lancet
Verified
Journal Article
Closed access
EAEmma Aitken
Emma Aitken
AJAndrew Jackson
Andrew Jackson
RKRachel Kearns
Rachel Kearns
MSMark Steven
Mark Steven
JKJohn Kinsella
John Kinsella
AMAlan Macfarlane
Alan Macfarlane

22 January 2013 in QJM: An International Journal of Medicine
Verified
Journal Article
Closed access
PDF file
EAE. Aitken
E. Aitken
CCC. Carruthers
C. Carruthers
LGL. Gall
L. Gall
LKL. Kerr
L. Kerr
CGC. Geddes
C. Geddes
DKD. Kingsmore
D. Kingsmore
Background: Deficiencies in management have been highlighted as contributory factors in the death of many patients with acute kidney injury (AKI). However, there is little evidence addressing the quality of care provided to patients with milder AKI. Aim: The aim of this study is to evaluate the quality of care provided to a non-select cohort of patients with AKI and evaluate discrepancies in causation, recognition and management. Design: Retrospective inception cohort study. Methods: Demographic data were collected for all 1577 patients admitted to a University Teaching Hospital during a 1-month period. Baseline, admission and peak creatinine were correlated with mortality and length of hospital admission. AKI was classified according to Kidney Disease Improving Global Outcomes criteria. A retrospective case note review of all patients with AKI was carried out to evaluate quality of documentation and clinical management of AKI. Multivariate analysis was undertaken to determine risk factors for AKI. Results: Incidence of AKI on admission was 4.6%. A further 10.3% developed AKI while in hospital. All cause mortality was 4-fold higher among patients with AKI compared with those without (19 vs. 3.8%; P < 0.001). Mortality was significantly higher in those patients who developed AKI while an in-patient compared with those with AKI on admission (27.3 vs. 11.8%; P < 0.001). Diabetes, clinician perception of frailty, age and treatment with angiotensin-converting enzyme inhibitor prior to admission were found to be independent risk factors for AKI. AKI was unrecognized in 23.5% of patients, two-thirds of whom were discharged without resolution of renal function. Significant weaknesses in management were poorly kept fluid balance charts (48.2%), failure to withhold nephrotoxic drugs (38.8%) and failure to act upon abnormal biochemistry (41%) in a timely fashion. Conclusions: AKI is common in hospitalized patients and associated with a significant increase in hospital stay and mortality. AKI is often found in conjunction with other organ failure and in many cases is not preventable. Nevertheless clinicians need to be more vigilant of small creatinine rises to permit early intervention particularly among elderly and frail patients.

1 March 2017 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
EAEmma Aitken
Emma Aitken
PTPeter Thomson
Peter Thomson
LBLeigh Bainbridge
Leigh Bainbridge
RKRam Kasthuri
Ram Kasthuri
BMBelinda Mohr
Belinda Mohr
DKDavid Kingsmore
David Kingsmore

1 December 2012 in Transplantation Proceedings
Verified
Journal Article
Closed access
EAE. Aitken
E. Aitken
SRS. Ramjug
S. Ramjug
LBL. Buist
L. Buist
DKD. Kingsmore
D. Kingsmore

5 August 2014 in The Journal of Vascular Access
Verified
Journal Article
Closed access
EAEmma L. Aitken
Emma L. Aitken
AJAndrew J. Jackson
Andrew J. Jackson
DKDavid B. Kingsmore
David B. Kingsmore
Purpose: Early cannulation arteriovenous grafts (ecAVGs), such as the GORE® Acuseal™, have “low bleed” properties permitting cannulation within 24 hours of insertion. They may provide an alternative to tunneled central venous catheters (and associated line complications) in patients requiring urgent vascular access. Methods: We present our early experience of 37 patients treated with the GORE® Acuseal™ ecAVG. Results: A total of 11 upper limb, 24 lower limb and 2 complex graft procedures were performed. Indications for ecAVG were as follows: bridge to transplantation (21.6%); bridge to arteriovenous fistula (AVF) maturation (8.1%); AVF salvage (8.1%); no native options (67.6%, including 17 patients with bilateral central vein stenosis); 36 AVGs (97.3%) were successfully cannulated. Mean time to first cannulation: 30.4±23.4 hours (range: 2–192). Primary and secondary patency rates at 3, 6 and 12 months were 64.9%, 48.6%, 32.4% and 70.2%, 59.4%, 40.5% respectively. The systemic bacteremia rate was 0.2 per 1,000 access days. There was one perioperative death. Other complications included hematoma at cannulation sites (n=9), pseudoaneurysm (n=3) and local infection at graft site (n=6). A total of 26 of 37 patients (70.6%) achieved a “personal vascular access solution”: bridge to transplantation (n=8), bridge to functioning AVF/interposition AVG (n=5), maintenance hemodialysis via ecAVG (n=13); death with functioning AVG (n=1). Conclusions: Early experience with the GORE® Acuseal™ is encouraging. Patency and bacteremia rates are at least comparable to standard polytetrafluoroethylene grafts. ecAVGs have permitted cannulation within 24 hours of insertion and line avoidance in the majority of patients. Nearly three-quarters of patients achieved a definitive “personal vascular access solution” from their ecAVG.

24 July 2020 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
EAEmma Aitken
Emma Aitken
RKRachel Kearns
Rachel Kearns
LGLucian Gaianu
Lucian Gaianu
AJAndrew Jackson
Andrew Jackson
MSMark Steven
Mark Steven
AMAlan Macfarlane
Alan Macfarlane
Significance Statement: Although arteriovenous fistulas (AVFs) are the vascular access modality of choice for patients with established renal failure, high early failure rates limit universal use. Brachial plexus block—regional anesthesia—at the time of AVF creation provides sympathetic blockade and produces venodilation; several studies have demonstrated associated improvement in AVF patency rates. The authors demonstrate for the first time that these perioperative changes translate into sustained improvement in functional patency at 1 year after AVF creation under regional anesthesia compared with local anesthesia. Cost-effectiveness analyses showed that this more labor-intensive technique resulted in net savings. These findings suggest that regional anesthesia has potential to improve AVF usage among the dialysis population, avoid complications of alternative access modalities, reduce surgical workload, and deliver cost savings to healthcare systems at large. Background: Regional anesthesia improves short-term blood flow through arteriovenous fistulas (AVFs). We previously demonstrated that, compared with local anesthesia, regional anesthesia improves primary AVF patency at 3 months. Methods: To study the effects of regional versus local anesthesia on longer-term AVF patency, we performed an observer-blinded randomized controlled trial at three university hospitals in Glasgow, United Kingdom. We randomly assigned 126 patients undergoing primary radiocephalic or brachiocephalic AVF creation to receive regional anesthesia (brachial plexus block; 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine) or local anesthesia (0.5% L-bupivacaine and 1% lidocaine). This report includes findings on primary, functional, and secondary patency at 12 months; reinterventions; and additional access procedures (primary outcome measures were previously reported). We analyzed data by intention to treat, and also performed cost-effectiveness analyses. Results: At 12 months, we found higher primary patency among patients receiving regional versus local anesthesia (50 of 63 [79%] versus 37 of 63 [59%] patients; odds ratio [OR], 2.7; 95% confidence interval [95% CI], 1.6 to 3.8; P=0.02) as well as higher functional patency (43 of 63 [68%] versus 31 of 63 [49%] patients; OR, 2.1; 95% CI, 1.5 to 2.7; P=0.008). In 12 months, 21 revisional procedures, 53 new AVFs, and 50 temporary dialysis catheters were required. Regional anesthesia resulted in net savings of £195.10 (US$237.36) per patient at 1 year, and an incremental cost-effectiveness ratio of approximately £12,900 (US$15,694.20) per quality-adjusted life years over a 5-year time horizon. Results were robust after extensive sensitivity and scenario analyses. Conclusions: Compared with local anesthesia, regional anesthesia significantly improved both primary and functional AVF patency at 1 year and is cost-effective. Clinical Trial registry name and registration number: Local Anaesthesia versus Regional Block for Arteriovenous Fistulae, NCT01706354